Nanoform has announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s CESS technology.
Results are expected before the end of Q2/2021.
Nanoform has now achieved all its near-term business targets for 2020 and 2021 announced in relation to the IPO. New near-term business targets, in addition to the previously (November 27th) announced “First Biologics PoC project in 2021”, will be communicated in the coming months, states the company.
A progression of Nanoform’s first GMP campaign
The clinical trial is a progression of Nanoform’s first GMP campaign. In the clinical trial, Nanoform will investigate the behavior of an oral immediate release nanoformed formulation of piroxicam, an anti-inflammatory drug. The study aims to support the potential development of fast-acting forms of piroxicam and other drugs by demonstrating the clinical utility of Nanoform’s CESS nanoforming technology.
Nanoform’s in vivo and in vitro results suggest that by significantly reducing the size of drug particles, Nanoform’s CESS nanoforming technology can improve the pharmacokinetic properties of piroxicam. Poor bioavailability and solubility are major causes of failure in the drug development pipeline.
“The first ever manufacturing of a nanoformed drug for a clinical study and dosing in humans truly represents exciting times for Nanoform, our clients and the industry. We proudly look forward to the study results before summer 2021,” said Edward Hæggström, Nanoform’s CEO.
Photo of Edward Hæggström: Nanoform